Market closed
Reviva Pharmaceuticals/$RVPH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
Ticker
$RVPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
15
Website
RVPH Metrics
BasicAdvanced
$41M
Market cap
-
P/E ratio
-$1.12
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$41M
52-week high
$5.67
52-week low
$0.60
Average daily volume
578K
Financial strength
Current ratio
0.388
Quick ratio
0.317
Total debt to equity
-0.832
Management effectiveness
Return on assets (TTM)
-335.99%
Return on equity (TTM)
366.13%
Valuation
Price to book
-4.15
Price to tangible book (TTM)
-4.15
Price to free cash flow (TTM)
-1.127
Growth
Earnings per share change (TTM)
-38.66%
3-year earnings per share growth (CAGR)
25.15%
What the Analysts think about RVPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Reviva Pharmaceuticals stock.
RVPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RVPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RVPH News
AllArticlesVideos
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·1 week ago
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
GlobeNewsWire·2 weeks ago
Reviva to Participate in the UBS Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Reviva Pharmaceuticals stock?
Reviva Pharmaceuticals (RVPH) has a market cap of $41M as of November 23, 2024.
What is the P/E ratio for Reviva Pharmaceuticals stock?
The price to earnings (P/E) ratio for Reviva Pharmaceuticals (RVPH) stock is 0 as of November 23, 2024.
Does Reviva Pharmaceuticals stock pay dividends?
No, Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Reviva Pharmaceuticals dividend payment date?
Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Reviva Pharmaceuticals?
Reviva Pharmaceuticals (RVPH) does not currently have a Beta indicator.